51. In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus.
- Author
-
Kirchhoff L, Dittmer S, Buer J, Rath PM, and Steinmann J
- Subjects
- Aspergillus fumigatus isolation & purification, Eurotiales isolation & purification, Exophiala isolation & purification, Humans, Microbial Sensitivity Tests, Mycoses drug therapy, Mycoses microbiology, Scedosporium isolation & purification, Acetamides pharmacology, Antifungal Agents pharmacology, Aspergillus fumigatus drug effects, Eurotiales drug effects, Exophiala drug effects, Piperazines pharmacology, Pyrimidines pharmacology, Pyrroles pharmacology, Scedosporium drug effects
- Abstract
In recent decades, invasive infections caused by fungal pathogens have been reported with increasing frequency. Concurrently, the rates of detected resistance mechanisms against commonly used antifungal agents in fungi are increasing. The need for novel antifungal drugs is thus imminent. In this study, the novel drug olorofim (F901318) was tested for its antifungal activity against the human fungal pathogens Lomentospora prolificans (n = 20), Scedosporium aurantiacum (n = 2), Scedosporium apiospermum (n = 6), Rasamsonia argillacea species complex (n = 23), Exophiala dermatitidis (n = 10) and azole-resistant Aspergillus fumigatus (ARAF) (n = 25) in an in vitro broth microdilution assay according to European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommendations. Whilst olorofim was ascertained to be effective against R. argillacea species complex [minimum inhibitory concentrations (MICs) of ≤0.008 mg/L], Scedosporium spp. (MICs of 0.032-0.5 mg/L), L. prolificans (MICs of 0.032-0.5 mg/L) and ARAF (MICs of ≤0.008-0.032 mg/L), the drug had an MIC of >4 mg/L against E. dermatitidis. These data demonstrate the antifungal activity of olorofim against a broad range of filamentous fungal pathogens., Competing Interests: Declaration of Competing Interest None declared., (Copyright © 2020 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF